As Of	Filer	Filing¹	For·On·As	Docs:Size	Issuer		Filing Agent

12/29/17  Nussbaum Ran                      3          Director²   2:18K  Eloxx Pharmaceuticals, Inc.       Toppan Merrill/FA        
12/29/17  Heft Robert                       3          Director²   2:14K  Eloxx Pharmaceuticals, Inc.       Toppan Merrill/FA        
12/29/17  Kleijwegt Martijn                 3          Director²   1:4K   Eloxx Pharmaceuticals, Inc.       Toppan Merrill/FA        
12/29/17  Pontifax (Cayman) IV L.P.         3          10% Owner²  6:65K  Eloxx Pharmaceuticals, Inc.       Toppan Merrill/FA        
          Pontifax (China) IV L.P.
          Pontifax (Israel) IV, L.P.
          Pontifax IV GP L.P.
          Pontifax Management 4 G.P. (2015) Ltd.
12/29/17  Kariv Tomer                       3          Director²   2:18K  Eloxx Pharmaceuticals, Inc.       Toppan Merrill/FA        
12/29/17  Avnur Zafrira                     3          Director²   2:12K  Eloxx Pharmaceuticals, Inc.       Toppan Merrill/FA        
12/29/17  Noiman Silvia                     3          Dir.,Off.²  2:16K  Eloxx Pharmaceuticals, Inc.       Toppan Merrill/FA        
12/29/17  Huertas Pedro                     3          Officer²    1:6K   Eloxx Pharmaceuticals, Inc.       Toppan Merrill/FA        
12/29/17  Veinrib Gadi                      3          Director²   2:12K  Eloxx Pharmaceuticals, Inc.       Toppan Merrill/FA        
12/29/17  Pontifax (Cayman) III, L.P.       3          10% Owner²  5:52K  Eloxx Pharmaceuticals, Inc.       Toppan Merrill/FA        
          Pontifax (Israel) III, L.P.
          Pontifax Management Fund III L.P.
          Pontifax Management III G.P. (2011) Ltd.
12/29/17  Shabtai Gilad                     3          10% Owner²  2:12K  Eloxx Pharmaceuticals, Inc.       Toppan Merrill/FA        
  1/2/18‡ Pontifax Mgmt 4 G.P. (2015) Ltd.  SC 13D     12/29/17   10:106M Eloxx Pharmaceuticals, Inc.       Toppan Merrill/FA        
          Pontifax (Cayman) III, L.P.³
          Pontifax (Cayman) IV L.P.³
          Pontifax (China) IV L.P.³
          Pontifax (Israel) III, L.P.³
          Pontifax (Israel) IV, L.P.³
          Pontifax IV GP L.P.³
          Pontifax Management Fund III L.P.³
          Pontifax Management III G.P. (2011) Ltd.³
12/29/17  Pontifax Mgmt III GP (2011) Ltd   SC 13D                10:106M Eloxx Pharmaceuticals, Inc.       Toppan Merrill/FA        
          Pontifax (Cayman) III, L.P.³
          Pontifax (Cayman) IV L.P.³
          Pontifax (China) IV L.P.³
          Pontifax (Israel) III, L.P.³
          Pontifax (Israel) IV, L.P.³
          Pontifax IV GP L.P.³
          Pontifax Management 4 G.P. (2015) Ltd.³
          Pontifax Management Fund III L.P.³
12/29/17  Shabtai Gilad                     SC 13G                 1:52K  Eloxx Pharmaceuticals, Inc.       Toppan Merrill/FA        
12/29/17  Catalyst CEL Management Ltd.      SC 13G                 6:141K Eloxx Pharmaceuticals, Inc.       Toppan Merrill/FA        
          Catalyst Cel Fund L.P.³
          Cel Catalyst China Israel Fund L.P.³
          Cel Catalyst China Israel General Partner Ltd.³
12/29/17  Technion Research & Dev Foun… Ltd SC 13G                 2:67K  Eloxx Pharmaceuticals, Inc.       Toppan Merrill/FA        
          Technion Investment Opportunities Fund L.P.³
12/29/17  LSP V Cooperatieve U.A.           SC 13D                 4:26M  Eloxx Pharmaceuticals, Inc.       Toppan Merrill/FA        
          LSP V Management B.V.³
12/29/17  GHS Partners Ltd.                 SC 13G                 5:111K Eloxx Pharmaceuticals, Inc.       Toppan Merrill/FA        
          GHS Partnership L.P.³
          Global Health Science Fund I, L.P.³

____________
‡	A non-Insider-Ownership Filing that was accepted after the SEC “closed” at 5:30:00pm ET.  The legal “Filed As Of” date may be the next, or another, day.
¹	Filing/Form Types:
	3	Initial Statement of Beneficial Ownership of Securities by an Insider — Form 3 { The Filer is an Insider² of the Issuer }.
	SC 13D	Statement of Acquisition of Beneficial Ownership by an “Active” Investor — Schedule 13D.
	SC 13G	Statement of Acquisition of Beneficial Ownership by a “Passive” Investor — Schedule 13G.
²	Insider:  The Filer is a Director, Officer, 10% Owner and/or Other “insider” of the Issuer.
³	Group Member:  A Registrant or non-Registrant party to this Filing made by a Group.